Zain Research, Llc
Welcome,         Profile    Billing    Logout  
 5 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schneider, Lon
S-CitAD, NCT03108846: Escitalopram for Agitation in Alzheimer's Disease

Active, not recruiting
3
187
Canada, US
Escitalopram, Lexapro, Placebo, non-applicable
JHSPH Center for Clinical Trials, National Institute on Aging (NIA)
Dementia
04/24
05/25
NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Active, not recruiting
2/3
225
Canada, US
Piromelatine 20 mg, Neu-P11, Placebo
Neurim Pharmaceuticals Ltd., Syneos Health
Alzheimer's Disease
06/25
06/25
REGEN-BRAIN©, NCT04838301: Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Recruiting
2
200
US
Allopregnanolone, Allo, Placebo
University of Arizona, National Institute on Aging (NIA), Syneos Health, University of Southern California, ADM Diagnostics
Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
03/26
04/26
Allo-IM, NCT03748303: Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study

Active, not recruiting
1
12
US
Allopregnanolone, Allo
University of Arizona, University of Southern California, Alzheimer's Association
Alzheimer Dementia
12/22
06/23
TRC-PAD, NCT04004767: Program: In-Clinic Trial-Ready Cohort

Completed
N/A
220
US
University of Southern California, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, Brigham and Women's Hospital, Cleveland Clinic Lou Ruvo Center for Brain Health
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
04/24
04/24
NoMAD, NCT03900273: Development of Novel Measures for Alzheimer's Disease Prevention Trials

Suspended
N/A
400
US
No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS), Preclinical Alzheimer's Cognitive Composite (PACC), Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-Cog), and Functional Assessment Questionnaire (FAQ)
New York State Psychiatric Institute, Columbia University, University of Southern California, Feinstein Institute for Medical Research, University of Miami
Healthy Participants
08/25
08/25
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Nand, Cheta
NCT01908192 / 2017-001168-39: Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

Terminated
2/3
60
US, RoW
NaBen®, Placebo
SyneuRx International (Taiwan) Corp
Schizophrenia
10/23
10/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schneider, Lon
S-CitAD, NCT03108846: Escitalopram for Agitation in Alzheimer's Disease

Active, not recruiting
3
187
Canada, US
Escitalopram, Lexapro, Placebo, non-applicable
JHSPH Center for Clinical Trials, National Institute on Aging (NIA)
Dementia
04/24
05/25
NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Active, not recruiting
2/3
225
Canada, US
Piromelatine 20 mg, Neu-P11, Placebo
Neurim Pharmaceuticals Ltd., Syneos Health
Alzheimer's Disease
06/25
06/25
REGEN-BRAIN©, NCT04838301: Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Recruiting
2
200
US
Allopregnanolone, Allo, Placebo
University of Arizona, National Institute on Aging (NIA), Syneos Health, University of Southern California, ADM Diagnostics
Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
03/26
04/26
Allo-IM, NCT03748303: Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study

Active, not recruiting
1
12
US
Allopregnanolone, Allo
University of Arizona, University of Southern California, Alzheimer's Association
Alzheimer Dementia
12/22
06/23
TRC-PAD, NCT04004767: Program: In-Clinic Trial-Ready Cohort

Completed
N/A
220
US
University of Southern California, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, Brigham and Women's Hospital, Cleveland Clinic Lou Ruvo Center for Brain Health
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
04/24
04/24
NoMAD, NCT03900273: Development of Novel Measures for Alzheimer's Disease Prevention Trials

Suspended
N/A
400
US
No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS), Preclinical Alzheimer's Cognitive Composite (PACC), Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-Cog), and Functional Assessment Questionnaire (FAQ)
New York State Psychiatric Institute, Columbia University, University of Southern California, Feinstein Institute for Medical Research, University of Miami
Healthy Participants
08/25
08/25
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
12/24
12/24
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Nand, Cheta
NCT01908192 / 2017-001168-39: Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

Terminated
2/3
60
US, RoW
NaBen®, Placebo
SyneuRx International (Taiwan) Corp
Schizophrenia
10/23
10/23

Download Options